[1]
|
Ye, Q., Wang, B. and Mao, J. (2020) The Pathogenesis and Treatment of the “Cytokine Storm” in COVID-19. Journal of Infection, 80, 607-613.
https://doi.org/10.1016/j.jinf.2020.03.037
|
[2]
|
AminJafari, A. and Ghasemi, S. (2020) The Possible of Immunotherapy for Covid-19: A Systematic Review. International Immunopharmacology, 83, Article ID: 106455. https://doi.org/10.1016/j.intimp.2020.106455
|
[3]
|
Veronese, N., Demurtas, J., Yang, L., et al. (2020) Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Frontiers in Medicine, 7, 170. https://doi.org/10.3389/fmed.2020.00170
|
[4]
|
WHO (2020) Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected.
https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf
|
[5]
|
Dexamethasone for COVID-19-Preliminary Report Effect of Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report RECOVERY Collaborative Group.
|
[6]
|
Shultz, M. (2007) Comparing Test Searches in PubMed and Google Scholar. Journal of the Medical Library Association, 95, 442-445.
https://doi.org/10.3163/1536-5050.95.4.442
|
[7]
|
Henderson, J. (2005) Google Scholar: A Source for Clinicians? CMAJ, 172, 1549-1550.
https://doi.org/10.1503/cmaj.050404
|
[8]
|
Mesel-Lemoine, M., Millet, J., Vidalain, P.-O., et al. (2012) A Human Coronavirus Responsible for the Common Cold Massively Kills Dendritic Cells but Not Monocytes. Journal of Virology, 86, 7577-7587. https://doi.org/10.1128/JVI.00269-12
|
[9]
|
Masters, P.S. (2006) The Molecular Biology of Coronaviruses. Advances in Virus Research, 65, 193-292. https://doi.org/10.1016/S0065-3527(06)66005-3
|
[10]
|
Wang, H., Li, X., Li, T., et al. (2020) The Genetic Sequence, Origin, and Diagnosis of SARS-CoV-2. European Journal of Clinical Microbiology and Infectious Diseases, 39, 1629-1635. https://doi.org/10.1007/s10096-020-03899-4
|
[11]
|
Kuljic-Kapulica, N. and Budisin, A. (1992) Coronaviruses. Srpski Arhiv za Celokupno Lekarstvo, 120, 215-218.
|
[12]
|
Stancioiu, F., Papadakis, G.Z., Kteniadakis, S., Izotov, B.N., Coleman, M.D., Spandidos, D.A. and Tsatsakis, A. (2020) A Dissection of SARS-CoV2 with Clinical Implications (Review). International Journal of Molecular Medicine, 489-508.
https://doi.org/10.3892/ijmm.2020.4636
https://www.spandidos-publications.com/ijmm/46/2/489
|
[13]
|
Ziebuhr, J. (2004) Molecular Biology of Severe Acute Respiratory Syndrome Coronavirus. Current Opinion in Microbiology, 7, 412-419.
https://doi.org/10.1016/j.mib.2004.06.007
|
[14]
|
Totura, A.L. and Bavari, S. (2019) Broad-Spectrum Coronavirus Antiviral Drug Discovery. Expert Opinion on Drug Discovery, 14, 397-412.
https://doi.org/10.1080/17460441.2019.1581171
|
[15]
|
Millet, J.K. and Whittaker, G.R. (2015) Host Cell Proteases: Critical Determinants of Coronavirus Tropism and Pathogenesis. Virus Research, 202, 120-134.
https://doi.org/10.1016/j.virusres.2014.11.021
|
[16]
|
Snijder, E.J., Decroly, E. and Zeibuhr, J. (2016) The Nonstrucutral Proteins Directing Coronavirus RNA Synthesis and Processing. In: Advances in Virus Research, Vol. 96, Academic Press, Cambridge, MA, 59-126.
https://doi.org/10.1016/bs.aivir.2016.08.008
|
[17]
|
Hagemeijer, M.C., Verheije, M.H., Ulasli, M., et al. (2010) Dynamics of Coronavirus Replication-Transcription Complexes. Journal of Virology, 84, 2134-2149.
https://doi.org/10.1128/JVI.01716-09
|
[18]
|
Mousavizadeh, L. and Ghasemi, S. (2020) Genotype and Phenotype of COVID-19: Their Roles in Pathogenesis. Journal of Microbiology, Immunology and Infection, in press. https://doi.org/10.1016/j.jmii.2020.03.022
|
[19]
|
Kim, Y., Jedrzejczak, R., Maltseva, N.I., et al. (2020) Crystal Structure of Nsp15 Endoribonuclease NendoU from SARS-CoV-2. Protein Science, 29, 1596-1605.
https://doi.org/10.1002/pro.3873
|
[20]
|
Fehr, A.R. and Perlman, S. (2015) Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier, H., Bickerton, E. and Britton, P. (Eds.), Coronaviruses: Methods and Protocols, Springer, New York, 1-23.
https://doi.org/10.1007/978-1-4939-2438-7_1
|
[21]
|
Wu, C., Liu, Y., Yang, Y., et al. (2020) Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods. Acta Pharmaceutica Sinica B, 10, 766-788. https://doi.org/10.1016/j.apsb.2020.02.008
|
[22]
|
Neuman, B.W., Chamberlain, P., Bowden, F. and Joseph, J. (2014) Atlas of Coronavirus Replicase Structure. Virus Research, 194, 49-66.
https://doi.org/10.1016/j.virusres.2013.12.004
|
[23]
|
Guarino, L.A., Bhardwaj, K., Dong, W., Sun, J., Holzenburg, A. and Kao, C. (2005) Mutational Analysis of the SARS Virus Nsp15 Endoribonuclease: Identification of Residues Affecting Hexamer Formation. Journal of Molecular Biology, 353, 1106-1117.
https://doi.org/10.1016/j.jmb.2005.09.007
|
[24]
|
Zhang, L., Li, L., Yan, L., et al. (2018) Structural and Biochemical Characterization of Endoribonuclease Nsp15 Encoded by Middle East Respiratory Syndrome Coronavirus. Journal of Virology, 92, e00893-18.
|
[25]
|
Joseph, J.S., Saikatendu, K.S., Subramanian, V., et al. (2007) Crystal Structure of a Monomeric Form of Severe Acute Respiratory Syndrome Coronavirus Endonuclease nsp15 Suggests a Role for Hexamerization as an Allosteric Switch. Journal of Virology, 81, 6700-3708. https://doi.org/10.1128/JVI.02817-06
|
[26]
|
Bhardwaj, K., Sun, J., Holzenburg, A., Guarino, L.A. and Kao, C.C. (2006) RNA Recognition and Cleavage by the SARS Coronavirus Endoribonuclease. Journal of Molecular Biology, 361, 243-256. https://doi.org/10.1016/j.jmb.2006.06.021
|
[27]
|
Bhardwaj, K., Guarino, L. and Kao, C.C. (2004) The Severe Acute Respiratory Syndrome Coronavirus Nsp15 Protein Is an Endoribonuclease That Prefers Manganese as a Cofactor. Journal of Virology, 78, 12218-12224.
https://doi.org/10.1128/JVI.78.22.12218-12224.2004
|
[28]
|
Deng, X. and Baker, S.C. (2018) An “Old” Protein with a New Story: Coronavirus Endoribonuclease Is Important for Evading Host Antiviral Defenses. Virology, 517, 157-163. https://doi.org/10.1016/j.virol.2017.12.024
|
[29]
|
Deng, X., Hackbart, M., Mettelman, R.C., et al. (2017) Coronavirus Nonstructural Protein 15 Mediates Evasion of dsRNA Sensors and Limits Apoptosis in Macrophages. Proceedings of the National Academy of Sciences of the United States of America, 114, E4251-E4260. https://doi.org/10.1073/pnas.1618310114
|
[30]
|
Duffy, S. (2018) Why Are RNA Virus Mutation Rates So Damn High? PLoS Biology, 16, E4251-E4260. https://doi.org/10.1371/journal.pbio.3000003
|
[31]
|
Pachetti, M., Marini, B., Benedetti, F., et al. (2020) Emerging SARS-CoV-2 Mutation Hot Spots Include a Novel RNA-Dependent-RNA Polymerase Variant. Journal of Translational Medicine, 18, Article No. 179.
https://doi.org/10.1186/s12967-020-02344-6
|
[32]
|
Sanjuán, R. and Domingo-Calap, P. (2016) Mechanisms of Viral Mutation. Cellular and Molecular Life Sciences, 73, 4433-4448.
https://doi.org/10.1007/s00018-016-2299-6
|
[33]
|
Regoes, R.R., Hamblin, S. and Tanaka, M.M. (2013) Viral Mutation Rates: Modelling the Roles of Within-Host Viral Dynamics and the Trade-Off between Replication Fidelity and Speed. Proceedings of the Royal Society B: Biological Sciences, 280, Article ID: 20122047. https://doi.org/10.1098/rspb.2012.2047
|
[34]
|
Eckerle, L.D., Becker, M.M., Halpin, R.A., et al. (2010) Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing. PLoS Pathogens, 6, e1000896.
https://doi.org/10.1371/journal.ppat.1000896
|
[35]
|
Hadfield, J., Megill, C., Bell, S.M., et al. (2018) NextStrain: Real-Time Tracking of Pathogen Evolution. Bioinformatics, 34, 4121-4123.
https://doi.org/10.1093/bioinformatics/bty407
|
[36]
|
Day, T., Gandon, S., Lion, S. and Otto, S.P. (2020) On the Evolutionary Epidemiology of SARS-CoV-2. Current Biology, 30, R849-R857.
https://doi.org/10.1016/j.cub.2020.06.031
|
[37]
|
Korber, B., Fischer, W.M., Gnanakaran, S., et al. (2020) Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus. Cell, 182, 812-827.E19. https://doi.org/10.1016/j.cell.2020.06.043
|
[38]
|
Yin, W., Mao, C., Luan, X., et al. (2020) Structural Basis for Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir. Science, 368, 1499-1504. https://pubmed.ncbi.nlm.nih.gov/32358203/
|
[39]
|
RECOVERY and RemdesivirV1.0 2020-05-27. https://www.recoverytrial.net/
|
[40]
|
Maruta, H. (2014) Herbal Therapeutics That Block the Oncogenic Kinase PAK1: A Practical Approach towards PAK1-Dependent Diseases and Longevity. Phytotherapy Research, 28, 656-672. https://doi.org/10.1002/ptr.5054
|
[41]
|
Zhao, Z. and Manser, E. (2012) PAK Family Kinases. Cellular Logistics, 2, 59-68.
https://doi.org/10.4161/cl.21912
|
[42]
|
Maruta, H. and He, H. (2020) PAK1-Blockers: Potential Therapeutics against COVID-19. Medicine in Drug Discovery, 6, Article ID: 100039.
https://doi.org/10.1016/j.medidd.2020.100039
|
[43]
|
Demestre, M., Messerli, S.M., Celli, N., et al. (2009) CAPE (Caffeic Acid Phenethyl Ester)-Based Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice. Phytotherapy Research, 23, 226-230.
https://doi.org/10.1002/ptr.2594
|
[44]
|
Wang, M., Cao, R., Zhang, L., et al. (2020) Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro. Cell Research, 30, 269-271. https://doi.org/10.1038/s41422-020-0282-0
|
[45]
|
Chen, I.-Y., Chang, S.C., Wu, H.-Y., et al. (2010) Upregulation of the Chemokine (C-C Motif) Ligand 2 via a Severe Acute Respiratory Syndrome Coronavirus Spike-ACE2 Signaling Pathway. Journal of Virology, 84, 7703-7712.
https://doi.org/10.1128/JVI.02560-09
|
[46]
|
Matsuyama, S., Kawase, M., Nao, N., et al. (2020) The Inhaled Corticosteroid Ciclesonide Blocks Coronavirus RNA Replication by Targeting Viral NSP15.
|
[47]
|
Fuller, P.J., Lim-Tio, S.S. and Brennan, F.E. (2000) Specificity in Mineralocorticoid versus Glucocorticoid Action. Kidney International, 57, 1256-1264.
https://doi.org/10.1046/j.1523-1755.2000.00959.x
|
[48]
|
Stockman, L.J., Bellamy, R. and Garner, P. (2017) SARS: Systematic Review of Treatment Effects. PLoS ONE, 12, e343.
|
[49]
|
Ramadan, A.A., Gaffin, J.M., Israel, E. and Phipatanakul, W. (2019) Asthma and Corticosteroid Responses in Childhood and Adult Asthma. Clinics in Chest Medicine, 40, 163-177. https://doi.org/10.1016/j.ccm.2018.10.010
|
[50]
|
Morra, M.E., van Thanh, L., Kamel, M.G., et al. (2018) Clinical Outcomes of Current Medical Approaches for Middle East Respiratory Syndrome: A Systematic Review and Meta-Analysis. Reviews in Medical Virology, 28, e1977.
https://doi.org/10.1002/rmv.1977
|
[51]
|
van der Velden, V.H.J. (1998) Glucocorticoids: Mechanisms of Action and Anti-Inflammatory Potential in Asthma. Mediators in Inflammation, 7, Article ID: 702547.
https://doi.org/10.1080/09629359890910
|
[52]
|
Barnes, P.J. (2010) Inhaled Corticosteroids. Pharmaceuticals, 3, 514-540.
https://doi.org/10.3390/ph3030514
|
[53]
|
Zhang, W., Zhao, Y., Zhang, F., et al. (2020) The Use of Anti-Inflammatory Drugs in the Treatment of People with Severe Coronavirus Disease 2019 (COVID-19): The Experience of Clinical Immunologists from China. Clinical Immunology, 214, Article ID: 108393. https://doi.org/10.1016/j.clim.2020.108393
|
[54]
|
Xu, Z., Shi, L., Wang, Y., et al. (2020) Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine, 8, 420-422. https://doi.org/10.1016/S2213-2600(20)30076-X
|
[55]
|
Rochwerg, B., Oczkowski, S.J., Siemieniuk, R.A.C., et al. (2018) Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Critical Care Medicine, 46, 1411-1420. https://doi.org/10.1097/CCM.0000000000003262
|
[56]
|
Villar, J., Ferrando, C., Martínez, D., et al. (2020) Dexamethasone Treatment for the Acute Respiratory Distress Syndrome: A Multicentre, Randomised Controlled Trial. The Lancet Respiratory Medicine, 8, 267-276.
https://doi.org/10.1016/S2213-2600(19)30417-5
|
[57]
|
Hardeman, H., Grutters, J.C., van de Garde, M.W., et al. (2011) Dexamethasone and Length of Hospital Stay in Patients with Community-Acquired Pneumonia: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 377, 2023-2053.
https://doi.org/10.1016/S0140-6736(11)60607-7
|
[58]
|
Annane, D., Bellissant, E., Bollaert, P.-E., et al. (2009) Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults: A Systematic Review. JAMA, 301, 2362-2375. http://www.bireme.br
|
[59]
|
Stein, S.W. and Thiel, C.G. (2017) The History of Therapeutic Aerosols: A Chronological Review. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 30, 20-41. https://doi.org/10.1089/jamp.2016.1297
|
[60]
|
Christie, P. (2004) Ciclesonide: A Novel Inhaled Corticosteroid for Asthma. Drugs of Today, 40, 569-576.
https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=4&p_RefId=850475&p_IsPs=N
|
[61]
|
Nave, R., Bethke, T.D., van Marle, S.P. and Zech, K. (2004) Pharmacokinetics of [14C]Ciclesonide after Oral and Intravenous Administration to Healthy Subjects. Clinical Pharmacokinetics, 43, 479-486.
https://doi.org/10.2165/00003088-200443070-00004
|
[62]
|
Nave, R., Watz, H., Hoffmann, H., Boss, H. and Magnussen, H. (2010) Deposition and Metabolism of Inhaled Ciclesonide in the Human Lung. European Respiratory Journal, 36, 1113-1119. https://doi.org/10.1183/09031936.00172309
|
[63]
|
Ukena, D. (2005) Ciclesonid—Ein neues inhalatives kortikosteroid. Pneumologie, 59, 689-695. https://doi.org/10.1055/s-2005-915570
|
[64]
|
Jeon, S., Ko, M., Lee, J., et al. (2020) Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrobial Agents and Chemotherapy, 64, e00819-20.
|
[65]
|
Choi, H.S., Kim, S.L., Kim, J.H. and Lee, D.S. (2020) The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells through Hedgehog Signaling-Mediated SOX2 Regulation. International Journal of Molecular Sciences, 21, 1014. https://doi.org/10.3390/ijms21031014
|
[66]
|
Allen, J.D., Jaffer, Z.M., Park, S.J., et al. (2009) P21-Activated Kinase Regulates Mast Cell Degranulation via Effects on Calcium Mobilization and Cytoskeletal Dynamics. Blood, 113, 2695-2705. https://doi.org/10.1182/blood-2008-06-160861
|
[67]
|
Vogelmeier, C.F., Hering, T., Lewin, T., Sander, P. and Bethke, T.D. (2011) Efficacy and Safety of Ciclesonide in the Treatment of 24,037 Asthmatic Patients in Routine Medical Care. Respiratory Medicine, 105, 186-194.
https://doi.org/10.1016/j.rmed.2010.09.016
|
[68]
|
Derendorf, H. (2007) Therapeutic Review: Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide. Journal of Clinical Pharmacology, 47, 782-789.
https://doi.org/10.1177/0091270007299763
|
[69]
|
Halpin, D.M.G., Faner, R., Sibila, O., Badia, J.R. and Agusti, A. (2020) Do Chronic Respiratory Diseases or Their Treatment Affect the Risk of SARS-CoV-2 Infection? The Lancet Respiratory Medicine, 8, 436-438.
https://doi.org/10.1016/S2213-2600(20)30167-3
|
[70]
|
Mahdavinia, M., Foster, K.J., Jauregui, E., et al. (2020) Asthma Prolongs Intubation in COVID-19. The Journal of Allergy and Clinical Immunology: In Practice, 8, 2388-2391. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224651/
|
[71]
|
Johnston, S.L. (2005) Overview of Virus-Induced Airway Disease. Proceedings of the American Thoracic Society, 2, 150-156.
|
[72]
|
Wu, C., Chen, X., Cai, Y., et al. (2020) Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 180, 934-943.
https://doi.org/10.1001/jamainternmed.2020.0994
|
[73]
|
Kurai, D., Saraya, T., Ishii, H. and Takizawa, H. (2013) Virus-Induced Exacerbations in Asthma and COPD. Frontiers in Microbiology, 4, 293.
https://doi.org/10.3389/fmicb.2013.00293
|
[74]
|
Yang, I.A., Clarke, M.S., Sim, E.H. and Fong, K.M. (2012) Inhaled Corticosteroids for Stable Chronic Obstructive Pulmonary Disease. Cochrane Database of Systematic Reviews, No. 7, CD002991. https://doi.org/10.1002/14651858.CD002991.pub3
|
[75]
|
Contoli, M., Pauletti, A., Rossi, M.R., et al. (2017) Long-Term Effects of Inhaled Corticosteroids on Sputum Bacterial and Viral Loads in COPD. European Respiratory Journal, 50, Article ID: 1700451. https://doi.org/10.1183/13993003.00451-2017
|
[76]
|
Schaller, T., Hirschbühl, K., Burkhardt, K., et al. (2020) Postmortem Examination of Patients with COVID-19. JAMA, 323, 2518-2520.
https://doi.org/10.1001/jama.2020.8907
|
[77]
|
van den Brand, J.M.A., Smits, S.L. and Haagmans, B.L. (2015) Pathogenesis of Middle East Respiratory Syndrome Coronavirus. Journal of Pathology, 235, 175-184.
https://doi.org/10.1002/path.4458
|
[78]
|
Ito, K., Ohmagari, N., Mikami, A. and Sugiura, W. (2020) Major Ongoing Clinical Trials for COVID-19 Treatment and Studies Currently Being Conducted or Scheduled in Japan. Global Health & Medicine, 2, 96-101.
https://doi.org/10.35772/ghm.2020.01034
|
[79]
|
Gralinski, L.E., Sheahan, T.P., Morrison, T.E., et al. (2018) Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio, 9, e01753-18. https://doi.org/10.1128/mBio.01753-18
|
[80]
|
Zhong, J., Tang, J., Ye, C. Dong, L. (2020) The Immunology of COVID-19: Is Immune Modulation an Option for Treatment? The Lancet Rheumatology, 2, E428-E436.
https://doi.org/10.1016/S2665-9913(20)30120-X
|
[81]
|
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S. and Manson, J.J. (2020) COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. The Lancet, 395, 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
|
[82]
|
Nakajima, K., Ogawa, F., Sakai, K., et al. (2020) A Case of Coronavirus Disease 2019 Treated with Ciclesonide. Mayo Clinic Proceedings, 95, 1296-1297.
https://doi.org/10.1016/j.mayocp.2020.04.007
|
[83]
|
Ito, K., Yokoyama, T., Oguri, A., et al. (2020) Case Report: A Case of COVID-19 Pneumonia That Did Not Worsen and Was Relieved by Early Administration of Favipiravir and Ciclesonide.
|
[84]
|
(2020) A Trial of Ciclesonide in Adults with Mild COVID-19. Clinical-Trials.gov.
https://clinicaltrials.gov/ct2/show/NCT04330586
|
[85]
|
Iwabuchi, K., Yoshie, K., Kurakami, Y., Takahashi, K., Kato, Y. and Morishima, T. (2020) Therapeutic Potential of Ciclesonide Inhalation for COVID-19 Pneumonia: Report of Three Cases. Journal of Infection and Chemotherapy, 26, 625-632.
https://doi.org/10.1016/j.jiac.2020.04.007
|
[86]
|
Al-Dorzi, H.M., al Harbi, S.A. and Arabi, Y.M. (2014) Antibiotic Therapy of Pneumonia in the Obese Patient: Dosing and Delivery. Current Opinion in Infectious Diseases, 27, 165-173. https://doi.org/10.1097/QCO.0000000000000045
|
[87]
|
Iannella, H., Luna, C. and Waterer, G. (2016) Inhaled Corticosteroids and the Increased Risk of Pneumonia: What’s New? A 2015 Updated Review. Therapeutic Advances in Respiratory Disease, 10, 235-255.
https://doi.org/10.1177/1753465816630208
|
[88]
|
Spagnolo, P., Balestro, E., Aliberti, S., et al. (2020) Pulmonary Fibrosis Secondary to COVID-19: A Call to Arms? The Lancet Respiratory Medicine, 8, 750-752.
https://doi.org/10.1016/S2213-2600(20)30222-8
|
[89]
|
Stein, R., Sherril, D.L., Morgan, W.J., Holberg, C.J., Halonen, M., Taussig, L., Wright, A. and Martinez, F.D. (1999) Respiratory Syncytial Virus in Early Life and Risk of Wheeze and Allergy by Age 13 Years. The Lancet, 354, 541-545.
https://www.sciencedirect.com/science/article/pii/S0140673698103215
https://doi.org/10.1016/S0140-6736(98)10321-5
|
[90]
|
Woods, J.A., Wheeler, J.S., Finch, C.K. and Pinner, N.A. (2014) Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. International Journal of COPD, 9, 421-430. https://doi.org/10.2147/COPD.S51012
|